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nfluence of Treatment Duration
ith a 600-mg Dose of Clopidogrel
efore Percutaneous Coronary Revascularization
avid E. Kandzari, MD,* Peter B. Berger, MD,* Adnan Kastrati, MD,† Steven R. Steinhubl, MD,‡
ulinda Mehilli, MD,† Franz Dotzer, MD,§ Jurriën M. ten Berg, MD, Franz-Josef Neumann, MD,¶
ildegard Bollwein, MD,# Josef Dirschinger, MD,# Albert Schömig, MD,†# for the ISAR-REACT
tudy Investigators
urham, North Carolina; Munich, Garmisch-Partenkirchen, and Bad Krozingen, Germany; Lexington, Kentucky;
nd Nieuwegein, the Netherlands
OBJECTIVES We examined clinical outcomes in the Intracoronary Stenting and Antithrombotic Regimen-
Rapid Early Action for Coronary Treatment (ISAR-REACT) trial based on the duration of
pretreatment with a 600-mg loading dose of clopidogrel.
BACKGROUND The influence of the treatment duration with a 600-mg dose of clopidogrel before
percutaneous coronary revascularization on early outcomes remains uncertain.
METHODS Among 2,159 patients with coronary disease who underwent percutaneous coronary inter-
vention (PCI) in the ISAR-REACT trial, we examined clinical outcomes relative to the
duration of pretreatment with a 600-mg dose of clopidogrel: (2 to 3 h, 3 to 6 h, 6 to 12 h,
or 12 h). Patients were randomly assigned to adjunctive therapy with abciximab or placebo
at the beginning of the study. The primary end point was a composite of death, myocardial
infarction, or urgent revascularization within 30 days after randomization.
RESULTS No significant differences were observed between patient groups regarding the duration of
pretreatment, irrespective of assignment to abciximab or placebo (p  0.27 for interaction
among abciximab/clopidogrel and placebo/clopidogrel treatment at each time interval).
Occurrence of major bleeding also did not differ according to time of initial clopidogrel
dosing.
CONCLUSIONS For low-to-intermediate risk patients treated with a 600-mg loading dose of clopidogrel
before PCI, incremental clinical benefit within the first 30 days from durations of
pretreatment 2 to 3 h was not evident. (J Am Coll Cardiol 2004;44:2133–6) © 2004 by
ublished by Elsevier Inc. doi:10.1016/j.jacc.2004.08.060the American College of Cardiology Foundation
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bombination antiplatelet therapy with aspirin and a thien-
pyridine has remarkably improved the outcome of patients
fter coronary artery stenting (1,2). Recently, the potential
enefit of thienopyridine administration before percutane-
us coronary intervention (PCI) has been examined. For
atients at low-to-intermediate risk for early ischemic com-
lications, treatment with clopidogrel at least several hours
o days before PCI may reduce early adverse events and
ossibly lessen the benefit provided by glycoprotein (GP)
Ib/IIIa antagonists (3–5). Recent trials have shown im-
roved outcomes with earlier clopidogrel treatment before
lective PCI, yet the appropriate dose and duration for
retreatment with clopidogrel remain uncertain.
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4-01), and by an unrestricted educational grant from Bristol-Myers Squibb GmbH,
unich, Germany.r
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ccepted August 23, 2004.More rapid platelet inhibition has been achieved with
arge loading doses of clopidogrel than with lower doses of
lopidogrel or with ticlopidine, yet at least 3 to 6 h is
ecessary to achieve the maximal antiplatelet effect ex vivo
ith a 300-mg loading dose (6–9). In the Clopidogrel for
he Reduction of Events During Observation (CREDO)
rial, despite a nonsignificant 19% relative reduction in
schemic adverse events with clopidogrel treatment (300
g) 3 to 24 h before PCI, a prespecified subgroup analysis
evealed that patients receiving pretreatment for 6 h
emonstrated a strong trend toward benefit, whereas those
reated for shorter periods did not (4). Subsequent analysis
f these data, however, have revealed that clinical events
ere not significantly reduced compared with placebo unless
00 mg of clopidogrel was given at least 15 h before PCI
10).
Accordingly, there may be adverse consequences if PCI is
erformed before achieving adequate platelet inhibition. A
00-mg loading dose of clopidogrel results in a maximal
ntiplatelet effect within 2 h of administration, as assessed
y light transmission aggregometry (6,11,12). Further, we
ecently demonstrated that the addition of a GP IIb/IIIa
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Clopidogrel Loading Interval December 7, 2004:2133–6ntagonist may not provide measurable clinical benefit for
atients receiving a 600-mg loading dose of clopidogrel at
east 2 h before PCI (5). In the Intracoronary Stenting and
ntithrombotic Regimen-Rapid Early Action for Coronary
reatment (ISAR-REACT) trial, the duration of clopi-
ogrel pretreatment beyond 2 h was not further specified.
e therefore examined clinical outcomes in ISAR-
EACT based on the duration of pretreatment after a
00-mg loading dose of clopidogrel.
ETHODS
tudy overview. The ISAR-REACT trial has been previ-
usly described (5). Between May 2000 and February 2003,
atients enrolled in the trial were treated with a 600-mg oral
oading dose of clopidogrel at least 2 h before elective PCI.
ll patients gave written informed consent, and the study
rotocol was approved by the ethics committees of the
articipating centers. The major exclusion criteria were a
yocardial infarction (MI) within 14 days, an acute coro-
ary syndrome manifest by ST-segment deviation0.1 mV
n at least two electrocardiographic leads at rest, a troponin
level 0.03 ng/ml, or insulin-dependent diabetes melli-
us. Other exclusion criteria were a target lesion that
nvolved a venous bypass graft, chronic (3 months) occlu-
ion, or angiographically visible thrombus; left ventricular
jection fraction 30%; any hemodynamic instability; or
reatment with an intravenous GP IIb/IIIa inhibitor within
he preceding 14 days.
In addition to clopidogrel, all patients received 325 to 500
g of aspirin. After diagnostic coronary angiography but
efore guide wire placement, patients were randomly as-
igned in a double-blinded fashion to adjunctive treatment
ith abciximab (0.250 mg/kg bolus, followed by a 0.125
g/kg/min infusion [up to 10 g/min] for 12 h) or placebo.
atients assigned to abciximab received 70 U/kg of unfrac-
ionated heparin compared with 140 U/kg for those as-
igned to placebo.
After stent placement, the protocol specified indefinite
spirin therapy (100 to 325 mg daily) and treatment with
lopidogrel, 75 mg twice daily until discharge, but no longer
han three days, followed by 75 mg daily for at least one
onth. Aside from in-hospital ascertainment of adverse
vents, follow-up was performed for patients experiencing
Abbreviations and Acronyms
CREDO  Clopidogrel for the Reduction of
Events During Observation trial
GP  glycoprotein
ISAR-REACT  Intracoronary Stenting and
Antithrombotic Regimen-Rapid Early
Action for Coronary Treatment trial
MI  myocardial infarction
PCI  percutaneous coronary intervention
ULN  upper limit of normalschemic symptoms within 30 days after randomization. ctudy hypothesis and end points. The hypotheses, end
oint definitions, and results of the ISAR-REACT trial
ave been described (5). The hypothesis of this analysis was
hat, among all patients undergoing PCI (either with
bciximab treatment or placebo), the composite 30-day end
oint of death, MI, or urgent repeat revascularization would
ot significantly differ based on the duration of pretreatment
ith clopidogrel. Hemorrhagic and hematologic complica-
ion rates were assessed. Myocardial infarction was defined
s the development of pathologic Q waves in two or more
ontiguous electrocardiographic leads or an elevation of
reatine kinase or creatine kinase-MB (3 the upper limit
f normal [ULN], minimum of two samples). All events
ere classified and adjudicated by a committee blinded to
he patients’ treatment assignments.
tatistical analysis. Categorical variables were compared
y the likelihood-ratio chi-square test. Continuous variables
re presented as mean values  SD and were compared by
ne-way analysis of variance. Logistic regression model
nalysis also was performed for the 30-day composite end
oint, to assess for an interaction between abciximab treat-
ent and duration of clopidogrel pretreatment, as well as
he independent role of duration of clopidogrel pretreat-
ent. This model included all baseline characteristics
Table 1). Thirty-day outcomes were also assessed by the
aplan-Meier method and compared by the log-rank test.
ll analyses were by intention-to-treat, and all p values are
wo-sided with significance level of 0.05.
ESULTS
f 2,159 patients enrolled in the study, four patient groups
ere identified based on the duration of clopidogrel treatment
efore PCI: 2 to 3 h, n  367; 3 to 6 h, n  560; 6 to 12 h,
 486; 12 h, n  746 (Table 1). Patients were further
ivided according to whether they received abciximab or
lacebo. The median duration of clopidogrel pretreatment was
.4 h (25th, 75th percentiles  4.0, 19.0 h).
The mean age of the study population was 66 years, 40%
ad class III or IV angina, and 20% had type 2 diabetes
ellitus (Table 1). Approximately 75% of patients had
ultivessel disease, and about 33% had experienced prior
I. Revascularization was performed on more than one
esion in 30% of patients (n 652; p 0.40 across groups).
The duration of clopidogrel therapy before PCI was not
ssociated with differences in the composite 30-day clinical
utcome or its individual components (Table 2). Patients
reated with 600 mg clopidogrel 2 to 3 h before intervention
ad event rates similar to those of patients receiving earlier
reatment (p  0.79 across groups) (Fig. 1). Neither the
ccurrence of large MI (creatine kinase or creatine
inase-MB 5 times the ULN) nor any infarction differed
etween patient groups. In addition, by using a multivari-
ble Cox regression model that examined 30-day adverse
vents, no independent role was observed for duration of
lopidogrel pretreatment (p  0.47) nor was there a
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December 7, 2004:2133–6 Clopidogrel Loading Intervalignificant interaction between duration of clopidogrel pre-
reatment and abciximab treatment (p  0.27). At 30 days,
he primary composite end point was 2.9% in the group
retreated for 2 to 3 h who did not receive abciximab versus
.6% in those who did (p  0.20).
Clopidogrel pretreatment appeared safe across all time
oints; as previously reported (5), no patient sustained an
ntracranial hemorrhage, and minor and major bleeding
pisodes did not differ between the four groups based on
retreatment duration. Mild thrombocytopenia and trans-
usion requirements increased with abciximab treatment (5),
ut did not differ among patients receiving clopidogrel
lone, irrespective of treatment duration.
ISCUSSION
linical trials have suggested improved outcomes for pa-
ients undergoing elective percutaneous revascularization
fter pretreatment with clopidogrel (3,4), yet the appropri-
te dose and duration of clopidogrel pretreatment have
emained uncertain. Our analysis indicates that, among
atients at low-to-intermediate risk for early ischemic com-
lications after elective PCI following pretreatment with a
00-mg loading dose of clopidogrel, increasing the pretreat-
ent interval beyond 2 to 3 h is not associated with a
easurable clinical benefit, irrespective of adjunctive treat-
ent with abciximab.
able 2. Clinical Outcomes at 30 Days According to Clopidogre
2–3 h
(n  367) (n
eath, n (%) 1 (0.3)
yocardial infarction, n (%) 15 (4.1) 2
rgent revascularization, n (%) 4 (1.1)
eath, myocardial infarction,
urgent revascularization, n (%)
16 (4.4) 2
ajor bleeding, n (%) 6 (1.6)
inor bleeding, n (%) 13 (3.5)
lood transfusion, n (%) 7 (1.9)
hrombocytopenia, n (%) 1 (0.3)
able 1. Patient Baseline Characteristics According to Timing of
2–3 h
(n  367)
ge (yrs) 65.2  10.0
omen, n (%) 84 (23)
ody mass index (kg/m2) 27.2  4.0
rterial hypertension, n (%) 213 (58)
iabetes, n (%) 78 (21)
urrent smoker, n (%) 55 (15)
ypercholesterolemia, n (%) 196 (53)
rior myocardial infarction, n (%) 119 (32)
rior aortocoronary bypass surgery, n (%) 33 (9)
ngina class III or IV, n (%) 141 (38)
ultivessel disease, n (%) 263 (72)
eft ventricular ejection fraction (%) 58.7  11.8
tatin therapy at admission 211 (58)
ata are presented as number of patients (%) or mean  SD.ata are presented as number of patients (%).Against the background of recent trials that have ad-
anced our understanding of thienopyridine therapy as
djunctive treatment for PCI, two contemporary random-
zed trials have shown that 300 mg of clopidogrel given at
he time of PCI followed by a daily 75-mg dose for at least
wo weeks is equivalent to conventional ticlopidine for
reventing early ischemic events and is superior to ticlopi-
ine with regard to hematologic and other side effects
13,14). In vitro studies using light transmission aggregom-
try have indicated that a 600-mg loading dose of clopi-
ogrel accelerates inhibition of platelet aggregation, as
ompared with a 300-mg loading dose of clopidogrel or a
00-mg dose of ticlopidine, and this effect is demonstrable
h after drug administration (12,15).
The results in this analysis contrast with the findings
rom the CREDO trial that demonstrated a time-
ependence in the clinical benefit of a 300-mg clopidogrel
oading dose, with at least 15 h of pretreatment required to
ignificantly reduce clinical events (10). These clinical re-
ults are in contrast with ex vivo studies suggesting that
00-mg of clopidogrel requires only 3 to 6 h to achieve
aximal effect (6–9). Conversely, the findings in the
resent analysis support the hypothesis that rapid platelet
nhibition when a 600-mg clopidogrel dose is administered
s concordant with the absence of further clinical benefit
eyond 2 to 3 h in the ISAR-REACT trial.
ding Dose Interval Before Percutaneous Coronary Intervention
0)
6–12 h
(n  486)
>12 h
(n  746) p Value
) 1 (0.2) 2 (0.3) 0.97
) 20 (4.1) 25 (3.4) 0.89
) 5 (1.0) 5 (0.7) 0.71
) 21 (4.3) 26 (3.5) 0.79
) 2 (0.4) 9 (1.2) 0.17
) 10 (2.1) 17 (2.3) 0.20
) 3 (0.6) 11 (1.5) 0.28
) 2 (0.4) 4 (0.5) 0.93
pidogrel Loading Dose
–6 h
 560)
6–12 h
(n  486)
>12 h
(n  746) p Value
7 10.6 67.1 9.8 65.2 10.1 0.01
0 (23) 123 (25) 172 (23) 0.79
1 3.8 27.1 3.8 27.2 3.8 0.92
5 (54) 273 (56) 381 (51) 0.12
9 (20) 104 (21) 150 (20) 0.85
0 (20) 81 (17) 129 (17) 0.30
9 (50) 286 (59) 392 (53) 0.03
3 (31) 129 (27) 282 (38)  0.001
8 (9) 46 (9) 80 (11) 0.59
7 (41) 211 (43) 290 (39) 0.37
8 (76) 362 (75) 549 (74) 0.41
3 12.5 60.7 13.2 58.2 11.7 0.007
8 (55) 233 (48) 475 (64)  0.001l Loa
3–6 h
 56
2 (0.4
1 (3.8
3 (0.5
5 (4.5
3 (0.5
8 (1.4
5 (0.9
3 (0.5Clo
3
(n
65.
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27.
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Clopidogrel Loading Interval December 7, 2004:2133–6Because patients in the ISAR-REACT trial were not
andomized according to the timing of clopidogrel pretreat-
ent, a limitation of the trial design is the ability to
efinitively establish the absence of a time-dependent rela-
ionship beyond 2 to 3 h with a 600-mg clopidogrel loading
ose. Although there were differences in baseline character-
stics between the four study groups, patients with a longer
nterval between clopidogrel treatment and revascularization
id not show a higher risk profile. The findings of the
resent study, however, inform the need for further pro-
pective, randomized examination of the relationship be-
ween the clopidogrel dose and pretreatment duration with
linical outcomes.
onclusions. When a 600-mg loading dose of clopidogrel is
dministered at least 2 h before PCI in patients considered at
ow or intermediate risk for ischemic complications, as in the
SAR-REACT trial, the likelihood of a successful procedural
utcome and freedom from early adverse events is not further
ncreased by prolonging the pretreatment interval of clopi-
ogrel, regardless of the additional use of abciximab.
eprint requests and correspondence: Dr. David E. Kandzari,
oom 7063, Duke Clinical Research Institute, Durham, North
arolina 27705. E-mail: kandz002@mc.duke.edu.
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